Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 [Radiation therapy (4 Gy vs. 24 Gy) in patients with indolent non-Hodgkins lymphoma: Results of the FORT Study].

Literature DB >> 25538992

[Radiation therapy (4 Gy vs. 24 Gy) in patients with indolent non-Hodgkins lymphoma: Results of the FORT Study].

Klaus Herfarth, Laila König.

Abstract

Entities: Disease Species

Mesh：

Year: 2014 PMID： 25538992 DOI： 10.1007/s00066-014-0728-8

Source DB: PubMed Journal: Strahlenther Onkol ISSN： 0179-7158 Impact factor: 3.621

× No keyword cloud information.

8 in total

Review 1. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Authors: B D Cheson; S J Horning; B Coiffier; M A Shipp; R I Fisher; J M Connors; T A Lister; J Vose; A Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; J O Armitage; W Carter; R Hoppe; G P Canellos
Journal: J Clin Oncol Date: 1999-04 Impact factor: 44.544

2. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506

3. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial.

Authors: Lisa Lowry; Paul Smith; Wendi Qian; Stephen Falk; Kim Benstead; Tim Illidge; David Linch; Martin Robinson; Andrew Jack; Peter Hoskin
Journal: Radiother Oncol Date: 2011-06-12 Impact factor: 6.280

4. Pretreatment with rituximab enhances radiosensitivity of non-Hodgkin's lymphoma cells.

Authors: Ira Skvortsova; Bela-Andre Popper; Sergej Skvortsov; Maria Saurer; Thomas Auer; Robert Moser; Hans Kamleitner; Heinz Zwierzina; Peter Lukas
Journal: J Radiat Res Date: 2005-06 Impact factor: 2.724

5. Potential role for low dose limited-field radiation therapy (2 x 2 grays) in advanced low-grade non-Hodgkin's lymphomas.

Authors: G Ganem; P Lambin; G Socié; T Girinsky; J Bosq; J L Pico; P Solal-Céligny; J M Cosset
Journal: Hematol Oncol Date: 1994 Jan-Feb Impact factor: 5.271

6. 4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial.

Authors: Peter J Hoskin; Amy A Kirkwood; Bilyana Popova; Paul Smith; Martin Robinson; Eve Gallop-Evans; Stewart Coltart; Timothy Illidge; Krishnaswamy Madhavan; Caroline Brammer; Patricia Diez; Andrew Jack; Isabel Syndikus
Journal: Lancet Oncol Date: 2014-02-24 Impact factor: 41.316

7. High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas.

Authors: R L M Haas; Ph Poortmans; D de Jong; B M P Aleman; L G H Dewit; M Verheij; A A M Hart; M H J van Oers; M van der Hulst; J W Baars; H Bartelink
Journal: J Clin Oncol Date: 2003-07-01 Impact factor: 44.544

8. Low-dose radiation therapy (2 Gy × 2) in the treatment of orbital lymphoma.

Authors: Carolina E Fasola; Jennifer C Jones; Derek D Huang; Quynh-Thu Le; Richard T Hoppe; Sarah S Donaldson
Journal: Int J Radiat Oncol Biol Phys Date: 2013-05-29 Impact factor: 7.038

8 in total

5 in total

[Radiation therapy (4 Gy vs. 24 Gy) in patients with indolent non-Hodgkins lymphoma: Results of the FORT Study].

Review 1. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

2. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

3. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial.

4. Pretreatment with rituximab enhances radiosensitivity of non-Hodgkin's lymphoma cells.

5. Potential role for low dose limited-field radiation therapy (2 x 2 grays) in advanced low-grade non-Hodgkin's lymphomas.

6. 4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial.

7. High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas.

8. Low-dose radiation therapy (2 Gy × 2) in the treatment of orbital lymphoma.

1. Radiotherapy of indolent orbital lymphomas : Two radiation concepts.

2. Low-dose total skin electron beam therapy for cutaneous lymphoma : Minimal risk of acute toxicities.

3. Response rates and recurrence patterns after low-dose radiotherapy with 4 Gy in patients with low-grade lymphomas.

4. Prospective Study of 4 Gy Radiotherapy for Orbital Mucosa-Associated Lymphoid Tissue Lymphoma (FORMAL).

Review 5. Radiotherapy for Non-Hodgkin's lymphoma: still standard practice and not an outdated treatment option.